News
Wall Street surged as the S&P 500 reclaimed 6,000, fueled by a strong jobs report. Discover market movers like Tesla, Moderna, and Procter & Gamble.
The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.
Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...
Despite uncertainties arising from new FDA policies around COVID-19 vaccines, Moderna has cleared the agency's desk with its ...
Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...
The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...
6d
MedPage Today on MSNFDA Approves Moderna's New Lower-Dose COVID-19 VaccineThe FDA's approval was based on a study of 11,400 people, ages 12 and older, that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least ...
The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...
The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...
According to Dr. Nina Gloriani who chaired the country’s vaccine expert panel during the pandemic, Filipinos who received Pfizer’s Comirnaty and Moderna’s Spikevax COVID-19 vaccines are not ...
The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results